Protavio is proud to announce its successful participation as a sponsor at the prestigious Biomarkers UK event, held in London this February. The event, a cornerstone for advancements in the biomarker industry, saw leading companies, academics, and researchers converge to discuss the latest in biomarker discovery, validation, and clinical implementation.
Protavio participated in the Biomarkers exhibition with a booth, captivating the attention of attendees with its cutting-edge multiplex proteomics technologies and comprehensive services, including biomarker discovery, validation, assay development, sample testing services, and in vitro diagnostic (IVD) production.
Highlighting the event was Protavio’s showcase of its collaboration on the Dioptra EU Cancer Mission project. This ambitious initiative focuses on the novel discovery of biomarkers for early colorectal cancer screening, employing both Olink and Luminex platforms to identify selective and specific biomarkers aimed at early diagnosis. The showcasing of DIOPTRA illustrated Protavio’s commitment to advancing cancer research through innovative technologies and collaborative efforts.
Protavio’s team was on hand to discuss the intricacies of biomarker discovery using Olink technology and the comprehensive process of assay development and manufacturing using the Luminex platform. The engagement at the booth was remarkable, with many visitors expressing keen interest in Protavio’s solutions and the potential impact on healthcare and patient outcomes.
Protavio extends its heartfelt thanks to all attendees who stopped by the booth, engaged in discussions, and showed interest in our technologies and projects.